The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase

Acta Haematol. 2011;126(4):241-5. doi: 10.1159/000330608. Epub 2011 Sep 27.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects*
  • Benzimidazoles
  • Benzoates / administration & dosage
  • Benzoates / pharmacology
  • Benzoates / therapeutic use*
  • Caspases / metabolism*
  • Cell Cycle / drug effects
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Deferasirox
  • Enzyme Activation / drug effects
  • HL-60 Cells
  • Humans
  • Injections, Intraperitoneal
  • Iron Chelating Agents / administration & dosage
  • Iron Chelating Agents / pharmacology
  • Iron Chelating Agents / therapeutic use*
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / metabolism
  • Leukemia, Myeloid / pathology
  • Mice
  • Mice, Nude
  • Neoplasm Proteins / metabolism*
  • Poly(ADP-ribose) Polymerases / metabolism
  • Proteolysis
  • Triazoles / administration & dosage
  • Triazoles / pharmacology
  • Triazoles / therapeutic use*
  • Tumor Burden / drug effects
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Benzimidazoles
  • Benzoates
  • Iron Chelating Agents
  • Neoplasm Proteins
  • Triazoles
  • emedastine
  • Poly(ADP-ribose) Polymerases
  • Caspases
  • Deferasirox